Clinical Trial Update: A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 neoadjuvant study in early-stage non-small cell lung cancer comparing nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-09-28